M. Gilmore

Currently Chief Scientific Officer, Mass Eye and Ear/Mass General Brigham and Sir William Osler Professor of Ophthalmology (Microbiology), Harvard Medical School, Mike also serves as Director of the Infectious Disease Institute, and as Co-Director of the Microbial Sciences Initiative of Harvard University. Additionally, he is a Senior Associate Member of the Broad Institute. As Principal Investigator of the NIH-funded Harvard-wide Program on Antibiotic Resistance, his research focuses on the evolution and development of multidrug resistant strains of enterococci, staphylococci, and streptococci, and the development of new therapeutics for treating infections of the eye, ear and other anatomical sites. He was named in “The Heroes of CRISPR” (Cell 2016 164(1-2):18-28.) as inspiring Broad Institute scientist interest in developing CRISPR as a tool for therapeutic gene editing. Mike has trained over 35 graduate students and postdocs, and is currently course coordinator and principle lecturer in OEB290/MICRO210 Microbiology: Chemistry, ecology and evolution. Outside of Harvard, he currently serves on the Board of Directors of the American Society for Microbiology (ASM), and is past chair of the NIH Bacterial Pathogenesis Study Section, the Gordon Conference on Microbial Adhesion and Signal Transduction, American Society for Microbiology (ASM) Division D, and the Association for Research in Vision and Ophthalmology (ARVO) IM Section. Mike is founder of the International Conference on Enterococci (ICE) series, and the Boston Area Antibiotic Resistance Network (BAARN). He recently served as chair of the US National Institutes of Health (NIH) blue ribbon panel for the Antimicrobial Resistance Diagnostic Challenge; and of Scientific Advisory Boards for the Zentrum für Infektionsforschung, University of Wuerzburg, and the Center for Antimicrobial Resistance and Therapeutic Discovery at Brown University. He started his academic career in 1984 at the University of Oklahoma Health Sciences Center, where he rose through the ranks to Vice President for Research. He also held the MG McCool professorship and was awarded the George Lynn Cross research chair. In 2004 he moved to Harvard Medical School as President and CEO of the Schepens Eye Research Institute, Marie and DeWalt Ankeny Director of Research and CL Schepens Professor of Ophthalmology. In 2010, he moved his laboratories to the Massachusetts General Hospital campus, in the Massachusetts Eye and Ear Infirmary. He has published over 200 peer reviewed manuscripts in Cell, Nature, Science, PNAS and other leading journals. He continues to serve on numerous advisory boards and committees for public and private organizations focused on drug discovery, antibiotic resistance, and bacterial pathogenesis.

Papers in database

7

Primary author

1 paper

Years active

2002 – 2020

Total publications

372

Total citations

23,209

h-index

83